ISIN:FR0012333284

EQS-News: Abivax präsentiert vier Abstracts zu Obefazimod zur Behandlung von Colitis ulcerosa auf dem 19. Kongress der Europ Crohn’s and Colitis Organisation (ECCO) und veranstaltet wissenschaftliches Symposium

Retrieved on: 
Tuesday, February 13, 2024
Abstract, Behandlung, Kolitis, Kongress, Euro, Organisation, ECCO, Symposion, The European, MEZ, Euronext, NASDAQ, Programm, Stadium, Entwicklung, Fokus, Arzneimittel, Immunantwort, Patient, CU, Tausch, Experte, Bereich, Doktor, MED, CMO, Plattform, Daten, Aufmerksamkeit, Wirkung, Stabilisierung, Titel, Zeughaus, Moa, Erweiterung, Raum, A12, Professor, M.S., Link, Registrierung, Information, Stand, NR

EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Retrieved on: 
Wednesday, February 7, 2024
Biostatistics, Research, Novartis, GxP, Therapy, Gastroenterology, Patient, Patient safety, Boston University, Public health, Euronext Paris, Epidemiology, Dana–Farber Cancer Institute, Amgen, Management

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Key Points: 
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    The issuer is solely responsible for the content of this announcement.
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality.
  • Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance.
  • If approved, it would be available to many patients who are in need of safe and long-term efficacious therapeutic options for chronic inflammatory diseases.”
    Ana Sharma joined Abivax from Takeda, where she held the position of Vice President, Global Head of Research and Development Clinical Quality Assurance.

EQS-News: Abivax ernennt Ana Sharma zur Vice President, Global Head of Quality

Retrieved on: 
Wednesday, February 7, 2024
Vice, Präsident, Global, Head, Quality, MEZ, Euronext, NASDAQ, Programm, Stadium, Entwicklung, Fokus, Arzneimittel, Immunantwort, Patient, Ernennung, Erfahrung, Industrie, Projekt, Bereich, Gastroenterologie, Immunologie, Microsoft Teams, Kommunikation, Inspektion, Pierre-Joseph Garidel, CEO, Sektor, Team, Fachkompetenz, Studie, VP, Rahmen, Verantwortung, Anforderung, Ziel, Markt, Option, Behandlung, Recherche, Positionen, Master, Health, Epidemiologie, Biostatistik, Boston, University, MA, Unternehmen, Sitz, Kolitis, Information, Folge, Public Health

EQS-News: Abivax gibt Update zu seinem klinischen Phase-2b-Entwicklungsprogramm mit Obefazimod zur Behandlung von mittelschwerem bis schwerem, aktivem Morbus Crohn

Retrieved on: 
Monday, February 5, 2024
Update, Behandlung, Anfang, Quartal, Daten, Lauf, MEZ, Euronext, NASDAQ, Programm, Stadium, Entwicklung, Fokus, Arzneimittel, Immunantwort, Patient, Anpassung, MC, FDA, Start, CMO, Freigabe, IND, Studiendesign, Weg, Studie, Ratschlag, Rahmen, Phase, Wirkung, Zeitmanagement, NEW, Anwendungssoftware, Unternehmen, Sitz, Kolitis, Information, Folge

EQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease

Retrieved on: 
Monday, February 5, 2024
CMO, MD, Therapy, Patient, IND, Shanda, New Drug Application, FDA, Euronext Paris, NDA, Pharmaceutical industry

Sheldon Sloan, MD, M Bioethics, CMO of Abivax, says: “The IND clearance by the FDA allows Abivax to move forward with the development of obefazimod for the treatment of Crohn’s disease.

Key Points: 
  • Sheldon Sloan, MD, M Bioethics, CMO of Abivax, says: “The IND clearance by the FDA allows Abivax to move forward with the development of obefazimod for the treatment of Crohn’s disease.
  • We are excited to begin the obefazimod CD program, which has the potential to provide a meaningful benefit to patients in a therapeutic area with a high unmet medical need.”
    The obefazimod Phase 2b clinical trial in moderately to severely active CD is a double-blind placebo-controlled trial, evaluating three obefazimod doses.
  • The revised trial design takes into account FDA recommendations provided in the frame of an initial Phase 2a IND submission.
  • These adjustments to the obefazimod CD clinical program are not expected to have an impact on the overall program budget and projected supplemental New Drug Application (sNDA) submission timeline.

EQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Retrieved on: 
Tuesday, January 30, 2024
Pediatrics, Northwestern University, Patient, Associate, UC, Personalized medicine, Nutrition, Euronext Paris, Division, Hepatology, Therapy, Ulcerative colitis, KOL, EST, Pharmaceutical industry

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Key Points: 
  • Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
    The issuer is solely responsible for the content of this announcement.
  • The event will feature Marla Dubinsky, MD, and Parambir Dulai, MD.
  • Along with Abivax’s management, they will be discussing the unmet medical need and current treatment landscape for patients suffering from ulcerative colitis (UC).
  • He serves as the Director of GI Clinical Trials and Precision Medicine, as well as Director of the Digestive Health Foundation Biorepository.

EQS-News: Abivax veranstaltet einen KOL-Event für Investoren zur Diskussion der klinischen Phase-2b-Daten und des Phase-3-Studiendesigns für Obefazimod an Patienten mit mittelschwerer bis schwerer aktiver CU

Retrieved on: 
Tuesday, January 30, 2024
MEZ, Euronext, NASDAQ, Programm, Stadium, Entwicklung, Fokus, Arzneimittel, Immunantwort, Patient, Organisation, Experte, Gebiet, Gastroenterologie, Veranstaltung, Dienstag, EST, Englische Sprache, MED, Bedarf, Behandlung, Kolitis, CU, Art Themen, Wirkung, Studiendesign, Phase, Professor, Carl Icahn, Medicine, Mount, Sinai, NEW, City, Abteilung, Henry Kravis, Hospital, Information, Arbeit, Erfolg, English, Hepatologie, Northwestern, University, Evanston, Direktor, Studie, Bereich, Health, Foundation, Unternehmen, Sitz, Folge